The CLINUVEL management team and Board had long formed and shared a vision to build a sustainable, diversified and fully integrated pharmaceutical company under one holding, where each subsidiary is eventually to operate under its own P&L.
In a recent Letter to Shareholders, CLINUVEL Chair Willem Blijdorp announced the Company has planned to add a fourth division to the Group: Manufacturing.
The Manufacturing Division is being established to facilitate the manufacture of novel formulations and products.
CLINUVEL retains extensive experience developing the novel SCENESSE® (afamelanotide 16mg) formulation, the first controlled-release, injectable, bioresorbable implant formulation containing a novel melanocortin drug. The Manufacturing Division will focus on the development of innovative, controlled-release systemic and topical formulations.
Long-term, the Manufacturing Division’s objective is to produce products for both CLINUVEL and third parties.
In building in-house expertise in manufacturing, CLINUVEL aims in time to offer its services to other biopharmaceutical companies in both the clinical and commercial stages of their development.
A full-service Contract Development & Manufacturing Organisation (CDMO) will operate at maximum capacity and allow for modular expansion. With specific expertise built and retained in-house CLINUVEL will be able to offer its research, development and production to other companies and research groups within the biopharmaceutical sector.
CLINUVEL opened its integrated Research, Development & Innovation Centre, under the VALLAURIX subsidiary in Singapore in August 2020.
VALLAURIX contains several laboratories, whereby a laboratory for biological material and processing is being added. The combination of integrated laboratories to further experimental knowledge with manufacturing facilities operating under Good Manufacturing Practice aims to add value to the CLINUVEL Group.